Pulmonary Artery Banding: Palliative Surgery for Congenital Heart Disease — Cost, Top Hospitals & Success Rates | MyMedicPlus

Pulmonary artery banding (PAB) is a palliative cardiac surgical procedure in which a constrictive band — typically a strip of polytetrafluoroethylene (PTFE), silicone, or Gore-Tex — is placed around the main pulmonary artery (MPA) to create a controlled stenosis. This reduces excessive pulmonary blood flow (Qp) in congenital heart defects characterised by large left-to-right shunts or in single-ventricle physiology requiring balanced circulation, thereby protecting the pulmonary vascular bed from the development of irreversible pulmonary arterial hypertension (Eisenmenger syndrome).

PAB was first described by Muller and Dammann in 1952 and was historically used as a staging operation before primary intracardiac repair — particularly in neonates and small infants in whom complete open-heart repair carried prohibitive early mortality. Although advances in cardiopulmonary bypass, myocardial protection, and neonatal cardiac surgery have made primary complete repair feasible for many defects (including large VSD), PAB retains an important role in specific clinical circumstances where staged palliation is preferable or necessary.

The procedure is performed under general anaesthesia via a left lateral thoracotomy (avoiding cardiopulmonary bypass) or median sternotomy, depending on associated cardiac anatomy. A band is placed around the MPA and tightened under continuous haemodynamic monitoring (direct arterial pressure, oxygen saturation) until target post-banding parameters are achieved.

PAB is classified as a palliative procedure: it does not correct the underlying structural defect. Definitive repair (e.g., VSD closure, atrioventricular canal repair, Fontan completion for single ventricle) follows when the infant has grown sufficiently to tolerate corrective surgery, typically at 6-18 months of age.

PAB is indicated for a specific subset of congenital heart defects in which uncontrolled pulmonary overcirculation poses an immediate threat to the pulmonary vasculature or where complete repair cannot be safely performed at presentation:

Large left-to-right shunt lesions:

• Large ventricular septal defect (VSD): Particularly in premature infants, low-birth-weight neonates (<2.5 kg), or infants with additional comorbidities (pulmonary disease, sepsis, non-cardiac congenital anomalies) where cardiopulmonary bypass carries excessive risk. PAB allows growth before complete repair.
• Atrioventricular septal defect (AVSD/complete AV canal): Large AVSDs with significant left-to-right shunt and uncontrolled heart failure in infants unsuitable for early primary repair. Particularly in Down syndrome children with coincident pulmonary hypertension who require protection before complete repair.
• Multiple muscular VSDs ("Swiss cheese" septum): Technically challenging to close completely at a single operation; PAB provides symptom relief and pulmonary protection while the child grows and some muscular VSDs may close spontaneously.
• Truncus arteriosus: Occasionally as palliation when immediate complete repair is not feasible, though primary repair is preferred.

Single ventricle physiology:

• Hypoplastic left heart syndrome (HLHS): In the hybrid Stage I palliation strategy (an alternative to the Norwood procedure), bilateral PAB + ductal stenting maintains systemic output while protecting pulmonary circulation. This avoids deep hypothermic circulatory arrest in an extremely fragile neonate.
• Single ventricle variants (tricuspid atresia, double-outlet RV with unbalanced circulation): PAB used to restrict pulmonary blood flow and achieve balanced Qp:Qs in preparation for Glenn (bidirectional cavopulmonary anastomosis) and eventually Fontan completion.
• Left ventricular preparation (LV training) for transposition after arterial switch: In patients with transposition of great arteries (TGA) presenting late (>4-6 weeks), PAB + systemic-to-pulmonary shunt is used to hypertrophy the subpulmonary LV before arterial switch operation.

Patient selection for PAB involves detailed echocardiographic, haemodynamic, and clinical assessment by a multidisciplinary congenital heart team:

Candidates for PAB over primary repair:

• Prematurity and low birth weight: Infants <34 weeks gestational age or <2.0-2.5 kg at surgery; cardiopulmonary bypass risk is substantially higher in this group due to haemodilution, inflammatory response, and post-bypass pulmonary oedema
• Haemodynamic instability or sepsis: An infant in cardiac failure, requiring inotropic support, or with active systemic infection is a higher-risk candidate for primary repair on bypass
• Complex additional anatomy: Associated anomalies (aortic arch obstruction, anomalous coronary origins) that increase operative complexity and risk
• Borderline ventricular size or function: When ventricular adequacy for biventricular repair is uncertain, interim palliation with PAB allows time for ventricular growth assessment

Pre-operative assessment:

• Echocardiography: Define anatomy, assess ventricular function, estimate RV systolic pressure, quantify shunt (pulmonary:systemic flow ratio Qp:Qs by velocity time integral), assess AV valve competence
• Cardiac catheterisation: Reserved for cases with suspected fixed pulmonary hypertension or complex anatomy not fully defined by echo; Wood units and vasoreactivity testing (nitric oxide, oxygen) determine pulmonary vascular resistance and reversibility
• CT angiography: Delineate pulmonary artery anatomy (branch PA size, origin) to plan band placement and subsequent surgical access
• Nutritional and metabolic optimisation: Correct metabolic acidosis, ensure adequate caloric intake, manage heart failure medically before elective surgery

The surgical approach and band type are tailored to the specific cardiac defect and anticipated duration of palliation:

Surgical approaches:

• Left lateral thoracotomy (third or fourth intercostal space): Preferred for isolated MPA banding, avoids sternotomy and associated risks (wound infection, sternal non-union in neonates); preserves sternal integrity for subsequent repair
• Median sternotomy: Used when associated procedures are required (arch repair, atrial septectomy) or when PAB is part of the hybrid HLHS approach requiring bilateral PA banding and ductal stenting through the pericardium

Band materials:

• Fixed PTFE / Gore-Tex band: A strip of PTFE of predetermined width (typically 2-3 mm wide) is placed around the MPA; band circumference estimated from empirical formulas (e.g., Trusler formula: C (mm) = 20 mm + weight in kg, modified by presence of single ventricle or cyanosis). Non-adjustable after placement.
• FloWatch-PAB (adjustable implantable device): A CE-marked hydraulic adjustable band controlled by a subcutaneous telemetric receiver. Allows post-operative transcutaneous adjustment of band tightness using an external controller without reoperation. Particularly useful in LV training for TGA (serial tightening required) and when growth-related adjustment is anticipated. Eliminates empirical guesswork of fixed bands.

Intraoperative haemodynamic targets after banding:

• Two-ventricle physiology (large shunt lesions): Post-banding proximal MPA (distal to band) systolic pressure <50% of aortic systolic pressure; Qp:Qs approximately 1.5:1; SpO2 maintained >90%
• Single ventricle physiology (HLHS, functional SV): Target SpO2 75-85% (balanced Qp:Qs ~1:1); aortic saturation = pulmonary saturation = mixed venous saturation; excessive restriction causes systemic hypoxia; insufficient restriction causes pulmonary flooding and systemic hypoperfusion
• Hybrid HLHS Stage I: Bilateral PABs placed on left and right branch PAs with simultaneous stenting of the ductus arteriosus under fluoroscopy/echocardiographic guidance; maintains both pulmonary and systemic circulations pending comprehensive Stage II repair

When correctly applied, PAB provides significant haemodynamic and survival benefits in appropriately selected patients:

Protection of pulmonary vasculature: The most critical benefit. Unprotected large left-to-right shunts expose the pulmonary arterioles to high pressure and high flow, causing progressive remodelling leading to irreversible pulmonary arterial hypertension (Eisenmenger syndrome) within 1-2 years of life. PAB prevents this fatal outcome by reducing pulmonary artery pressure and flow until corrective surgery is feasible.

Allows growth and maturation: PAB buys time for the infant to grow — body weight is strongly associated with cardiopulmonary bypass survival. Many centres will delay complete repair until weight exceeds 4-5 kg for optimal bypass outcomes. Infant growth on PAB with appropriate feed supplementation (high-calorie formula, nasogastric feeding) allows planned repair in a substantially safer setting.

Avoids bypass in the highest-risk neonates: Cardiopulmonary bypass in premature or very low birth weight infants carries disproportionate inflammatory injury, pulmonary oedema, and coagulopathy. PAB through a thoracotomy avoids all bypass-associated risks, often completed in 45-90 minutes.

Ventricular retraining for arterial switch: In late-presenting TGA with regressed LV (after pulmonary band removal at 4-6 weeks post-arterial switch in early repair centres), PAB + shunt progressively increases LV afterload, retraining the ventricle to sustain systemic workload within 1-2 weeks, enabling subsequent arterial switch.

Hybrid HLHS benefit: The hybrid approach avoids the Norwood procedure — the highest-risk single-stage neonatal operation (30-day mortality 5-20% at major centres) — deferring comprehensive reconstruction to a less vulnerable stage.

PAB is a palliative procedure with inherent risks related to the operation itself and to the subsequent physiology of a banded circulation:

Intraoperative and immediate post-operative risks:

• Over-banding (excessive restriction): Causes acute right ventricular failure (RV outflow obstruction), profound systemic hypoxia (SpO2 <70%), and cardiovascular collapse. Requires immediate surgical band loosening. This is the most critical intraoperative risk.
• Under-banding: Insufficient restriction fails to protect the pulmonary vasculature and does not control heart failure. Requires reoperation for band tightening.
• Branch pulmonary artery distortion: The band may angulate or migrate proximally, causing distortion of the left or right PA origin — potentially complicating subsequent corrective surgery and requiring patch augmentation at the time of repair.
• Chylothorax: Lymphatic duct injury at thoracotomy; managed with medium-chain triglyceride diet or pleurodesis

Medium-term complications:

• Band migration: Distal or proximal migration of the band into the PA wall or toward a branch PA; detected on echocardiography by accelerating band gradient and changing site of maximal velocity
• Subaortic obstruction (AVSD-specific): Following PAB in atrioventricular septal defects, the banded right ventricular output may shift ventricular septal position, causing dynamic subaortic obstruction. Reported incidence 10-20% in some series; may necessitate earlier complete repair than planned.
• RV hypertrophy and dysfunction: Chronic RV pressure overload from the band leads to RV myocardial hypertrophy, which must be carefully reversed after band removal at the time of complete repair.
• Pulmonary artery stenosis at band site: Even after band removal, residual stenosis at the banding site may require patch plasty of the MPA at corrective surgery.

Children with PAB require close cardiological surveillance between the time of banding and definitive repair:

Outpatient monitoring (every 4-8 weeks):

• Echocardiography to assess band gradient (target 30-60 mmHg for biventricular physiology), ventricular function, AV valve regurgitation, PA anatomy, and body weight trajectory
• Pulse oximetry: Target SpO2 75-85% (single ventricle) or >90% (biventricular with large shunt)
• Growth and nutritional assessment: Weight faltering despite adequate caloric support may indicate under-banding or associated cardiac failure
• FloWatch adjustment (if fitted): Transcutaneous band adjustment performed non-invasively in clinic to maintain target haemodynamics as the child grows

Timing of complete repair:

• Large VSD / AVSD: Definitive intracardiac repair (VSD closure on bypass, AV canal repair) typically performed at 6-12 months of age when weight >5 kg; earlier if symptoms of heart failure persist despite adequate banding or if band complications develop
• Single ventricle (Fontan pathway): Glenn procedure (bidirectional cavopulmonary anastomosis) at 4-6 months; Fontan completion at 2-4 years
• Hybrid HLHS: Comprehensive Stage II (Norwood reconstruction + Glenn) at 4-6 months under circulatory arrest
• LV training for TGA: Arterial switch performed 1-2 weeks after rapid LV retraining is confirmed by echocardiographic assessment of LV wall thickness and pressure

Band removal at repair: The band is divided and excised at the time of corrective surgery. PA reconstruction (patch augmentation, Lecompte manoeuvre in TGA repair) addresses any residual banding site stenosis or PA distortion.

PAB is performed as a staged palliative operation — total treatment cost reflects both the banding procedure and the subsequent definitive repair:

PAB procedure costs:

• Open thoracotomy PAB (fixed band): USD 15,000-35,000 in the US including PICU care (typically 3-7 days); hospital stay is shorter than cardiopulmonary bypass operations
• Adjustable FloWatch device adds approximately USD 3,000-6,000 to implant costs but eliminates reoperation costs for band adjustment
• Hybrid HLHS procedure (bilateral PAB + ductal stenting): USD 30,000-60,000 due to hybrid suite requirements and combined catheter/surgical team

Subsequent repair costs (to be budgeted):

• VSD closure or AV canal repair on bypass: USD 40,000-80,000 in the US; substantially lower in India (USD 5,000-12,000) and Thailand (USD 8,000-15,000)
• Total staged palliation cost for single ventricle (PAB + Glenn + Fontan): USD 150,000-400,000 in the US over 3-4 years

Medical tourism for congenital heart surgery: India has become a global destination for paediatric cardiac surgery, with centres such as AIIMS New Delhi, Narayana Health, and Apollo Hospitals performing hundreds of complex CHD repairs annually at 10-20% of US costs. International accreditation (JCI, NABH) and experienced paediatric cardiac surgical teams with ECMO support are key quality benchmarks for families considering treatment abroad.

Insurance and cost assistance: In many countries, congenital heart surgery in children is publicly funded (NHS in UK; government schemes in India such as Ayushman Bharat for low-income families). Charitable organisations (Gift of Life International, Children's HeartLink) provide financial assistance for low-income patients accessing surgery abroad.

Advances in neonatal cardiac surgery have reduced the role of PAB in some conditions, but it remains essential in others where no suitable alternative exists:

• Primary complete repair without staging: For large VSDs in term, well-grown infants (>3.5 kg) without comorbidities, primary VSD closure on cardiopulmonary bypass can be performed at 3-6 months with excellent outcomes (30-day mortality <1% at high-volume centres). This avoids the need for two operations and the risks of band-related complications. Most experienced centres prefer primary repair over PAB for isolated large VSD in stable infants.
• Hybrid Norwood procedure: An alternative to the classical Norwood operation for HLHS, involving bilateral PAB and ductal stenting performed jointly by a cardiac surgeon and interventional cardiologist. Compared to the classical Norwood (full bypass in a neonate), the hybrid approach avoids bypass and deep hypothermic arrest but requires a more complex Stage II reconstruction. Outcomes data continue to mature; centres vary in their preference.
• Classical Norwood operation (Stage I palliation): The traditional alternative to hybrid PAB for HLHS — reconstructs the aorta and places a modified Blalock-Taussig shunt or Sano RV-PA conduit for pulmonary blood flow. High-risk neonatal operation; 30-day mortality 5-20% at experienced centres.
• Medical management of heart failure: Diuretics, ACE inhibitors, and high-calorie feeding can temporarily control heart failure symptoms in large-shunt lesions, potentially deferring surgery, but do not protect the pulmonary vasculature from long-term damage and are not a substitute for surgical intervention.
• Catheter-based VSD closure: Transcatheter VSD device closure is feasible for perimembranous VSDs in children >5-8 kg but is not suitable for large muscular or inlet VSDs, and is not available in the neonatal period.